<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658877</url>
  </required_header>
  <id_info>
    <org_study_id>14-01160</org_study_id>
    <nct_id>NCT02658877</nct_id>
  </id_info>
  <brief_title>Sputum-derived Cellular Targets After Xolair (Omalizumab)</brief_title>
  <official_title>In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify additional mechanisms of action of
      omalizumab that will lead to improved stratification of patients for treatment. Understanding
      the response of specific innate immune effector cells in the lung can provide clues to these
      questions. Investigators will use non-invasive measures of a discrete cell population to
      examine the downstream effects of omalizumab treatment in the lung. Information derived from
      these studies will help clarify mechanisms of action of omalizumab and help identify
      potential tools for patient endotyping and stratification for therapeutic interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double blind, 16-week intervention study to show
      feasibility and proof of concept. Analysis of whole induced sputum is under development for
      endotyping for asthma, allowing sampling of rare cells from conducting airways, repeated
      sampling, and cell-specific detailed genomic evaluation. Investigators have developed a novel
      technique to simultaneously enrich innate immune cells from sputum. This technique allows for
      in situ analyses of sputum-derived human bronchial epithelial cells (sHBEC). The non-invasive
      nature of the technique provides a unique tool for in vivo human studies.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting subjects
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Two Group T-test in Moderate Persistent Asthma</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Two Group T-test in Moderate Persistent Asthma</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of Omalizumab on Changes sHBEC Targets (Gene Expression Array) Compared Using Two-group T-test if Data</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Asthma Control Test</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lung Function Measure by Spirometry Test</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Measures of Small Airway Dysfunction Using Impulse Oscillometry</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Cufflinks.</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Gene Analyses</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Effect of Omalizumab on Gene &quot;Signature&quot; Generation Analyzed Using Gene Analysis Techniques</measure>
    <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
    <arm_group_label>Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
    <other_name>corticosteroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician diagnosed asthma

          -  Lung function (one or more of the following documented in the 5 years before
             enrollment or demonstration during screening) 1. Bronchial hyper responsiveness (BhR)
             confirmed by ≥ 12% improvement in FEV1 post bronchodilator within the previous 5
             years, or 2. Methacholine PC20 &lt; 16mg/dl within the previous 5 years

          -  Severity Criteria: Moderate-persistent asthma defined by the American Thoracic Society
             (ATS)

          -  Asthma Control: Partly or uncontrolled asthma according to GINA 2012 guidelines (at
             least three of the following features: daytime symptoms more than 2 times/week,
             limitation of activities, nocturnal symptoms, need for rescue inhaler &gt; 2 times/week,
             FEV1 &lt;80% predicted)

          -  Stable use of moderate-high dose inhaled corticosteroids in previous 3 months
             (definition derived from GINA 2012 guidelines: e.g. fluticasone propionate &gt;250
             mcg/day, budesonide &gt; 400mcg/day)

          -  Ability to perform induced sputum maneuvers

          -  Presence of elevated allergen IgE to any perennial aeroallergen

        Exclusion Criteria:

          -  Pulmonary function: FEV1 ≤ 70% predicted

          -  Any major chronic illness including but not limited to Chronic Obstructive Pulmonary
             Disease (COPD), uncontrolled hypertension, coronary artery disease, bronchiectasis,
             congestive heart failure, stroke, cystic fibrosis, insulin-dependent diabetes
             mellitus, renal failure, liver disorders, immunodeficiency state, or other condition
             that would interfere with participation in the study

          -  Current or &gt; 10 pack a year pack-year tobacco use

          -  Any investigational study within previous 1 month

          -  Inability to perform baseline measurements

          -  Inability to contact by telephone

          -  Pregnancy at screening and failure to use double barrier pregnancy protection in woman
             of childbearing age

          -  Hypersensitivity reaction to omalizumab in the past

          -  Exceeds limits of dosing table (IgE &lt;30 or 700 IU/ml) or body weight of &lt;30 or &gt; 150kg

          -  Systemic corticosteroids within the previous month

          -  Known malignant neoplasm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Reibman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <results_first_submitted>September 4, 2019</results_first_submitted>
  <results_first_submitted_qc>September 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xolair</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>asthma</keyword>
  <keyword>long-acting beta-agonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02658877/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab</title>
          <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>None were on placebo because study had a block randomization of 6.</population>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab</title>
          <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Two Group T-test in Moderate Persistent Asthma</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>Most (n=124) of these patients failed screening criteria and investigator did not move forward</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Two Group T-test in Moderate Persistent Asthma</title>
          <population>Most (n=124) of these patients failed screening criteria and investigator did not move forward</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement in the Reduction of the Effect of Omalizumab on Thymic Stromal Lymphopoietin (TSLP) Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Two Group T-test in Moderate Persistent Asthma</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Two Group T-test in Moderate Persistent Asthma</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement in the Reduction of the Effect of Omalizumab on IL-33 Gene Expression Using Nonparametric Wilcoxon in sHBEC in Moderate Persistent Asthma</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Omalizumab on Changes sHBEC Targets (Gene Expression Array) Compared Using Two-group T-test if Data</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Omalizumab on Changes sHBEC Targets (Gene Expression Array) Compared Using Two-group T-test if Data</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Asthma Control Test</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Asthma Control Test</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lung Function Measure by Spirometry Test</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lung Function Measure by Spirometry Test</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Measures of Small Airway Dysfunction Using Impulse Oscillometry</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Measures of Small Airway Dysfunction Using Impulse Oscillometry</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Cufflinks.</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Cufflinks.</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Gene Analyses</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Omalizumab on Newly Identified sHBEC Targets (Gene Expression) Analyzed Using Gene Analyses</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Effect of Omalizumab on Gene &quot;Signature&quot; Generation Analyzed Using Gene Analysis Techniques</title>
        <time_frame>16 Weeks of Treatment of omalizumab or placebo</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Omalizumab on Gene &quot;Signature&quot; Generation Analyzed Using Gene Analysis Techniques</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 Months</time_frame>
      <desc>0 Patients were on placebo</desc>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab</title>
          <description>Omalizumab: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient’s pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joan Reibman</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212 263 6479</phone>
      <email>Joan.Reibman@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

